Cargando…
Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?
Despite the significant progress in Rheumatoid Arthritis (RA) therapeutics, there are several reports in the literature claiming that the size of unmet needs in RA is large. In the era before biologics, there was indeed a significant number of patients who did not achieve low disease activity (LDA)...
Autores principales: | Drosos, Alexandros A., Pelechas, Eleftherios, Voulgari, Paraskevi V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722985/ https://www.ncbi.nlm.nih.gov/pubmed/31426398 http://dx.doi.org/10.3390/jcm8081237 |
Ejemplares similares
-
Golimumab for Rheumatoid Arthritis
por: Pelechas, Eleftherios, et al.
Publicado: (2019) -
Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis
por: Pelechas, Eleftherios, et al.
Publicado: (2019) -
Anti-Rheumatic Drugs May Ameliorate the Clinical Course and Outcome of COVID-19 In Rheumatoid Arthritis Patients
por: Pelechas, Eleftherios, et al.
Publicado: (2022) -
A not-to-miss Cause of Severe Cervical Spine Pain in a Patient with Rheumatoid Arthritis: A Case-Based Review
por: Drosos, Alexandros A., et al.
Publicado: (2021) -
Seronegative Erosive Arthritis Following SARS-CoV-2 Infection
por: Drosos, Alexandros A., et al.
Publicado: (2021)